

OSSIX® Plus

Ossifying Collagen Barrier Membrane

For Guided Bone Regeneration (GBR) & Guided Tissue Regeneration (GTR) Procedures

Ordering Information

OSSIX Plus is currently available in countries on all continents including the USA, Europe, Argentina, Canada, Chile, Colombia, Dominican Republic, Hong Kong, Israel, Korea, Mexico, Russia, Singapore, and Taiwan.

OSSIX Plus is available in 3 sizes:

Description & Size	Reference No.	Catalog No.
OSSIX Plus 15x25 mm	OX1525	700064
OSSIX Plus 25x30 mm	OX2530	700200
OSSIX Plus 30x40 mm	OX3040	700201

Datum Dental at a Glance

Datum Dental Ltd., a subsidiary of Datum Biotech, provides innovative dental regeneration products, aiming to support and enhance the future of implantology and oral care. Its patented GLYMATRIX core technology, a sugar cross-linking collagen biomaterial, is clinically proven in over 100 scientific publications with extensive clinical experience spanning two decades. Powered by GLYMATRIX, the OSSIX product family has enabled clinicians in hundreds of thousands of procedures worldwide to safely provide predictable, long-term results to their patients. Datum Dental continues to develop new products for GBR and GTR that simplify procedures and overcome major deficiencies in existing biomaterials through safe and transformational solutions.

Global Partners

USA:

Dentsply Sirona Implants, MIS Implants Technologies Inc., Orapharma, Inc., Sweden & Martina Inc.

Outside of USA:

Andes HSG, Bicon Singapore, Conectores Osteomaxilofaciales, H&A Systems Ltd., Hesira Med Inc., Med-Tech Esthetics LLC, Memodent B.V., MIS Implants (Belgium, Columbia, Romania, South Africa), P. Sideris & Co. E.E. - PS Team, Purgo, REGEDENT, Salugraft Dental, Sweden & Martina SpA, Syncrotech, VitalTech.

Everything we do is designed to give nature its best chance

datumdental

For more information on OSSIX regenerative products and activities in your region:

www.ossixdental.com     

© 2018 Datum Dental, Ltd. All rights reserved. The Datum Dental logo, GLYMATRIX and OSSIX are trademarks and/or registered trademarks of Datum Dental Ltd, Datum Biotech Ltd, their subsidiaries, and/or affiliates in the United States and/or other countries. All other company or product names are the trademarks or registered trademarks of their respective holders.

MKT0037 ver02


OSSIX® Plus

Ossifying Collagen Barrier Membrane

For Guided Bone Regeneration (GBR) & Guided Tissue Regeneration (GTR) Procedures

Powered by Clinically Proven GLYMATRIX® Technology

datumdental



OSSIX® Plus - Ossifying Collagen Barrier Membrane for GBR & GTR Procedures

Powered by GLYMATRIX® Technology

GLYMATRIX is a proprietary collagen cross-linking technology, similar to the naturally occurring glycation process in the human body. The clinically proven technology uses sugars to cross-link collagen molecules producing a collagen matrix, which is bioprogrammable and can be tailored to deliver products of varying physical properties and customized longevity.

OSSIX Plus Features & Benefits

OSSIX Plus is a resilient resorbable collagen barrier membrane:

- Maintains barrier functionality for 4-6 months
- Resistant to degradation when exposed for 3-5 weeks
- Excellent handling properties, adapts and conforms to defects, and adheres well to tissue
- Porcine derived, provides excellent biocompatibility

OSSIX Plus is Intended for Use During GBR & GTR Procedures


- Ridge augmentation for later implant insertions
- Simultaneous ridge augmentation and implant insertions
- Ridge augmentation around implants inserted in delayed extraction sites
- Ridge augmentation around implants inserted in immediate extraction sites
- Alveolar ridge preservation consequent to tooth (teeth) extraction(s)
- Over the window in lateral window sinus elevation procedure
- In implants with vertical bone loss due to infection, only in cases where satisfactory debridement and implant surface disinfection can be achieved
- In intra bony defects around teeth
- For treatment of recession defects, together with coronally positioned flap
- In furcation defects in multi-rooted teeth

Please read IFU before use and for additional info on indications, contraindications, warnings and precautions.

OSSIX Plus Ossifying Barrier Membrane Long-Term Results: 13 Year Post-op



Lateral Ridge Augmentation
L-R: Pre-op, procedure, and 13 years post-op
Courtesy of Bach Le, DDS, MD, FICD, FACD



Look for this signature herringbone pattern on both sides of the device

Barrier Function with True Ossification


Ossification is defined as the formation of bone, the state of being changed into a bony substance. OSSIX Plus is the only barrier membrane that ossifies.

Long-Term Effect on Bone Formation



Long-term follow-up of OSSIX Plus barrier membrane ossification up to 5 years post-op.

Human Histology 4-6 Months Post-op



Human histology at 4-6 months post-op shows bone promotion and ossification of OSSIX Plus barrier membrane

OSSIX Plus the Only Ossifying Barrier Membrane — Supporting Publications

To the best of our knowledge, these are the first reports of complete ossification of a collagen barrier membrane in GBR procedures.

- Zubery et al. (2007). Ossification of a novel cross-linked porcine collagen barrier in guided bone regeneration in dogs. J Periodontol 78:112- 121.
- Zubery et al. (2008). Ossification of a collagen membrane cross-linked by sugar: a human case series. J Periodontol. 79:101-1107.
- Tal H, Kozlovsky A, Artzi Z, Nemcovsky CE, Moses O. (2008) Long-term bio-degradation of cross-linked and non-cross-linked collagen barriers in human guided bone regeneration. Clin Oral Implants Res. 19(3):295-30.
- Capri G, Smukler H, Landi L. (2012) A less invasive approach to mandibular horizontal ridge augmentation using autogenous bone: A human histological case series. The Journal of Implants and Advanced Clinical Dentistry 4:27-36.
- Artzi Z, Weinreb M, Carmeli G, Lev-Dor R, Dard M, Nemcovsky CE. (2008) Histomorphometric assessment of bone formation in sinus augmentation utilizing a combination of autogenous and hydroxyapatite/biphasic tricalcium phosphate graft materials: at 6 and 9 months in humans. Clin. Oral Impl. Res. 19; 686-692.